{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T21:22:24Z","timestamp":1789593744084,"version":"build-2803163510"},"reference-count":18,"publisher":"American Society for Microbiology","issue":"3","license":[{"start":{"date-parts":[[2000,3,1]],"date-time":"2000-03-01T00:00:00Z","timestamp":951868800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2000,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            The efficacy of intravenous injection of FK463, a novel water-soluble lipopeptide, was evaluated in mouse models of disseminated candidiasis and aspergillosis and was compared with those of fluconazole (FLCZ) and amphotericin B (AMPH-B). In the candidiasis model, FK463 significantly prolonged the survival of intravenously infected mice at doses of 0.125 mg\/kg of body weight or higher. In disseminated candidiasis caused by\n            <jats:italic>Candida<\/jats:italic>\n            species, including FLCZ-resistant\n            <jats:italic>Candida albicans<\/jats:italic>\n            , FK463 exhibited an efficacy 1.4 to 18 times inferior to that of AMPH-B, with 50% effective doses (ED\n            <jats:sub>50<\/jats:sub>\n            s) ranging from 0.21 to 1.00 mg\/kg and 0.06 to 0.26 mg\/kg, respectively, and was much more active than FLCZ. The protective effect of FK463 was not obviously influenced by the fungal inoculum size, the starting time of the treatment, or the immunosuppressed status of the host. The reduction in efficacy was less than that observed with FLCZ or AMPH-B. The efficacy of FK463 was also evaluated in the disseminated candidiasis target organ assay and was compared with those of FLCZ and AMPH-B. Efficacies were evaluated on the basis of a comparison between the mean log\n            <jats:sub>10<\/jats:sub>\n            CFU in kidneys in the groups treated with antifungal agents and that in control group. A single dose of FK463 at 0.5 mg\/kg or higher significantly reduced the viable counts in kidneys compared with the numbers of yeast cells before treatment, and its efficacy was comparable to that of AMPH-B, while FLCZ at 4 mg\/kg showed only a suppressive effect on the growth of\n            <jats:italic>C. albicans<\/jats:italic>\n            in the kidneys. In the disseminated aspergillosis model, FK463 given at doses of 0.5 mg\/kg or higher significantly prolonged the survival of mice infected intravenously with\n            <jats:italic>Aspergillus fumigatus<\/jats:italic>\n            conidia. The efficacy of FK463 was about 2 times inferior to that of AMPH-B, with ED\n            <jats:sub>50<\/jats:sub>\n            s ranging from 0.25 to 0.50 mg\/kg and 0.11 to 0.29 mg\/kg, respectively. These results indicate that FK463 may be a potent parenterally administered therapeutic agent for disseminated candidiasis and aspergillosis.\n          <\/jats:p>","DOI":"10.1128\/aac.44.3.614-618.2000","type":"journal-article","created":{"date-parts":[[2002,7,27]],"date-time":"2002-07-27T10:06:42Z","timestamp":1027764402000},"page":"614-618","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":127,"title":["Efficacy of FK463, a New Lipopeptide Antifungal Agent, in Mouse Models of Disseminated Candidiasis and Aspergillosis"],"prefix":"10.1128","volume":"44","author":[{"given":"Fumiaki","family":"Ikeda","sequence":"first","affiliation":[{"name":"<!--label omitted: 1-->Medicinal Biology Research Laboratories1 and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshimi","family":"Wakai","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Medicinal Biology Research Laboratories1 and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Medicinal Biology Research Laboratories1 and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuyuki","family":"Maki","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Medicinal Biology Research Laboratories1 and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etsuko","family":"Watabe","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Medicinal Biology Research Laboratories1 and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichi","family":"Tawara","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Medicinal Biology Research Laboratories1 and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Goto","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Medicinal Biology Research Laboratories1 and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Watanabe","sequence":"additional","affiliation":[{"name":"<!--label omitted: 2-->Research Planning,2 Fujisawa Pharmaceutical Co., Ltd., Kashima, Yodogawa-ku, Osaka 532-8514,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumio","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"<!--label omitted: 3-->Kanagawa Prefectural Nursing and Hygienic School Hospital, 1-6, Shiomidai, Isogo-ku, Yokohama 235-0022,3 and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shogo","family":"Kuwahara","sequence":"additional","affiliation":[{"name":"<!--label omitted: 4-->Toho University School of Medicine, Ohmori Nishi, Ohta-ku, Tokyo 143-8540,4 Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.11.2333"},{"key":"e_1_3_2_3_2","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1093\/clinids\/11.3.369","article-title":"New spectrum of fungal infections in patients with cancer.","volume":"11","author":"Anaisse E.","year":"1989","unstructured":"Anaisse E. Bodey G. P. Kantarjian H. Ro J. Vartivarian S. E. Hopfer R. Hoy J. Polston K. New spectrum of fungal infections in patients with cancer. Rev. Infect. Dis. 11 1989 369 378","journal-title":"Rev. Infect. Dis."},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01963467"},{"key":"e_1_3_2_5_2","doi-asserted-by":"crossref","first-page":"86S","DOI":"10.1016\/0002-9343(91)90349-3","article-title":"Secular trends in nosocomial primary bloodstream infections in the United States.","volume":"91","author":"Banerjee S. N.","year":"1991","unstructured":"Banerjee S. N. Emori T. G. Culver D. H. Gaynes R. P. Jarvis W. R. Horan T. Edwards J. R. Tolson J. Henderson T. Martone W. J. the National Nosocomial Infections Surveillance System Secular trends in nosocomial primary bloodstream infections in the United States. Am. J. Med. 91 (Suppl. 3B) 1991 86S 89S","journal-title":"Am. J. Med."},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.mi.22.100168.000511"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/167.5.1247"},{"key":"e_1_3_2_8_2","doi-asserted-by":"crossref","first-page":"S133","DOI":"10.1093\/clinids\/22.Supplement_2.S133","article-title":"Lipid formulations of amphotericin B: recent progress and future directions.","volume":"22","author":"Hiemenz J. W.","year":"1996","unstructured":"Hiemenz J. W. Walsh T. J. Lipid formulations of amphotericin B: recent progress and future directions. Clin. Infect. Dis. 22 (Suppl. 2) 1996 S133 S144","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.37.9.1962"},{"key":"e_1_3_2_10_2","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1128\/JCM.36.10.2950-2956.1998","article-title":"Comparison of the in vitro activities of the new triazole SCH56592 and the echinocandin MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts.","volume":"36","author":"Ingroff A. E.","year":"1998","unstructured":"Ingroff A. E. Comparison of the in vitro activities of the new triazole SCH56592 and the echinocandin MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J. Clin. Microbiol. 36 1998 2950 2956","journal-title":"J. Clin. Microbiol."},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.26.4.446"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.5.1105"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.10.2726"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.11.2898"},{"key":"e_1_3_2_15_2","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1128\/AAC.41.8.1835","article-title":"In vitro antifungal activity of pneumocandin L-743,872 against a variety of clinically important molds.","volume":"41","author":"Poeta M. D.","year":"1997","unstructured":"Poeta M. D. Schell W. A. Perfect J. R. In vitro antifungal activity of pneumocandin L-743,872 against a variety of clinically important molds. Antimicrob. Agents Chemother. 41 1997 1835 1836","journal-title":"Antimicrob. Agents Chemother."},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.32.9.2092-2098.1994"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/17.3.269"},{"key":"e_1_3_2_18_2","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1128\/AAC.42.4.873","article-title":"Efficacy of LY303366 against amphotericin B-susceptible and -resistant Aspergillus fumigatus in a murine model of invasive aspergillosis.","volume":"42","author":"Verweiji P. E.","year":"1998","unstructured":"Verweiji P. E. Oakley K. L. Morrissey J. Morrissey G. Denning D. W. Efficacy of LY303366 against amphotericin B-susceptible and -resistant Aspergillus fumigatus in a murine model of invasive aspergillosis. Antimicrob. Agents Chemother. 42 1998 873 878","journal-title":"Antimicrob. Agents Chemother."},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.4.863"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.44.3.614-618.2000","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.44.3.614-618.2000","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T16:40:25Z","timestamp":1645461625000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.44.3.614-618.2000"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,3]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2000,3]]}},"alternative-id":["10.1128\/AAC.44.3.614-618.2000"],"URL":"https:\/\/doi.org\/10.1128\/aac.44.3.614-618.2000","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,3]]},"assertion":[{"value":"1999-05-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"1999-12-10","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2000-03-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}